82 Abstracts PMH13 PMH14 USE OF OLANZAPINE AND RISPERIDONE AT BASELINE IN A PROSPECTIVE STUDY OF THE COURSE OF TREATMENT FOR SCHIZOPHRENIA Johnstone BM 1 , Dulisse BK 2 , Loosbrock DL 1 , Gibson PJ 1 1 Health Outcomes Evaluation Group, Eli Lilly and Company, Indianapolis, IN, USA; 2 Statistical and Mathematical Sciences, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: To profile utilization of olanzapine and risperidone at baseline in a prospective study of treat- ment for schizophrenia, and evaluate factors associated with the receipt of these medications. METHODS: Data were obtained from the US Schizophrenia Care and As- sessment Program (US-SCAP), a prospective study of treatment for schizophrenia in six large community sys- tems of care. The first 1,231 patients enrolled in the study were evaluated, including 321 patients treated with olanzapine and 231 patients treated with risperidone. RESULTS: 45 percent of patients received olanzapine and/or risperidone over a six-month baseline interval. Olanzapine-treated patients received a median dose of 10.4 mg/day [mean 13.0, mode 10]. Risperidone-treated patients received a median dose of 6.0 mg/day [mean 5.6, mode 6]. Among patients receiving both medications, ris- peridone was two times more likely to precede olanza- pine than the reverse order. Patients initiating treatment with olanzapine were significantly more likely to receive prior treatment with clozapine and/or depot antipsychot- ics (P  0.01) than risperidone-treated patients. Patients treated with olanzapine only were significantly less likely to receive antiparkinsonian or anticholinergic agents (P  0.01) during the treatment interval than patients treated with risperidone only. CONCLUSIONS: Dosages of olanzapine and risperidone in this large community sample of patients receiving usual care were consistent with expectations from controlled studies. Olanzapine- treated patients were more likely to receive prior thera- pies associated with treatment resistance or noncompli- ance than risperidone-treated patients, suggesting the possibility of greater severity in the olanzapine treatment group. Olanzapine-treated patients were less likely to re- ceive antiparkinsonian or anticholinergic medications during therapy. PMH15 UTILIZATION OF ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA IN A MANAGED CARE POPULATION Nichol MB 1 , Harada ASM 1 , Jones JP 1 , McCombs JS 1 , Grogg A 2 , Gilderman A 3 , Vaccaro J 4 1 Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA, USA; 2 Janssen Pharmaceutica, West Trenton, NJ, USA; 3 Prescription Solutions, Costa Mesa, CA, USA; 4 PacifiCare Behavioral Health, Inc., Van Nuys, CA, USA Schizophrenia affects less than 1% of the US population, yet its treatment accounts for more than 2.5% of total healthcare expenditures, making it the most costly illness to treat in psychiatry. OBJECTIVES: The purpose of this study is to document the treatment experience of patients with schizophrenia in a managed care population. METHODS: This study utilized an administrative claims database from PacifiCare in California. Prescription and encounter claims from 1/1/95–9/1/99 in California, Texas, Oklahoma, Washington and Oregon were evalu- ated using an intent-to-treat analysis. Only adults were included, with 6 prior months eligibility, no antipsy- chotic medication use in the 120 days before treatment start (washout period), continuous antipsychotic use for 120 days, and 365 days of eligibility following treat- ment start. RESULTS: Of the 4,388 PacifiCare members qualifying for this analysis, only 232 (5%) had a diagno- sis of schizophrenia in the 180 days prior to the treat- ment start. In 4,321 (98%) of the antipsychotic treatment episodes, a single antipsychotic agent was initiated. Of those initiating antipsychotic mono-therapy, 3,286 (76%) WITHDRAWN